Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00425932
Status:
COMPLETED
Last Update Posted:
2013-08-22
First Post:
2007-01-22
Brief Title:
Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis
Sponsor:
Gaylis Norman B MD
Organization:
Gaylis Norman B MD
Study Overview
Official Title:
Impact of Rituximab on Magnetic Resonance Imaging Evidence of Synovitis and Bone Lesions in Patients With Moderate or Severe Rheumatoid Arthritis
Status:
COMPLETED
Status Verified Date:
2013-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to further investigate rituximab in the treatment of rheumatoid arthritis and to evaluate magnetic resonance imaging of the joints as a possible method to improve the evaluation of treatments
Detailed Description:
Rituximab is a monoclonal antibody that has been approved for the treatment of non-Hodgkins B cell lymphoma a type of cancer and for certain patients with rheumatoid arthritis RA by the Food and Drug Administration FDA To date more than 1000 subjects with rheumatoid arthritis have received rituximab in clinical studies
Magnetic resonance imaging MRI is a modern and sensitive method of looking at joints in people with rheumatoid arthritis It uses a magnetic field to create an image The MRI takes an image in 3 dimensions and this provides a better picture for a physician to see more details
There are two treatment groups in this study with equal numbers of patients assigned to each group All the patients will receive their baseline Methotrexate and two intravenous infusions 2 weeks apart of one of the following
1000 mg rituximab or
placebo Patients outcomes will be compared between the 2 groups After week 24 open label phase the patients will receive rituximab if rheumatoid arthritis remains active
All the patients will have MRI of their dominant hand and wrist with and without gadolinium performed at baseline 12 24 and 48 weeks on 15 Tesla MRI Some patients will also have additional MRI of the same hand and wrist without gadolinium at the same time points on 02 Tesla MRI Comparison of the images from the two machines will be performed
Various blood biomarkers will also be examined compared between the 2 treatment groups and correlated with the MRI results
Magnetic resonance imaging MRI is a modern and sensitive method of looking at joints in people with rheumatoid arthritis It uses a magnetic field to create an image The MRI takes an image in 3 dimensions and this provides a better picture for a physician to see more details
There are two treatment groups in this study with equal numbers of patients assigned to each group All the patients will receive their baseline Methotrexate and two intravenous infusions 2 weeks apart of one of the following
1000 mg rituximab or
placebo Patients outcomes will be compared between the 2 groups After week 24 open label phase the patients will receive rituximab if rheumatoid arthritis remains active
All the patients will have MRI of their dominant hand and wrist with and without gadolinium performed at baseline 12 24 and 48 weeks on 15 Tesla MRI Some patients will also have additional MRI of the same hand and wrist without gadolinium at the same time points on 02 Tesla MRI Comparison of the images from the two machines will be performed
Various blood biomarkers will also be examined compared between the 2 treatment groups and correlated with the MRI results
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None